The FDA approved Besivance (besifloxacin 0.6% ophthalmic suspension, from Bausch & Lomb) for the treatment of bacterial conjunctivitis, commonly referred to as “pink eye.”  This approval is based on a series of eight clinical trials designed to test the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics with the topical antibacterial. In three multi-center, randomized, double-masked trials involving nearly 2,400 patients, investigators found that Besivance treatment resulted in a greater proportion of patients experiencing clinical resolution and microbial eradication, when compared to its vehicle.

Besivance, a broad-spectrum ophthalmic fluoroquinolone, will be available by prescription in U.S. pharmacies in the second quarter of 2009.

For more information call (800) 323-0000 or visit